| Date | Title | Description |
| 20.06.2025 | Novadip receives RMAT designation for NVD003, its regenerative treatment for congenital pseudarthosis of the tibia | Novadip is developing NVD003, an autologous therapy derived from adipose stem cells, as a potential single treatment to save limbs and restore mobility in patients with CPT
The RMAT designation is part of the IND that Novadip obtained for N... |
| 12.06.2025 | AstriVax Therapeutics Further Strengthens Team with the Appointment of Dieter Weinand as New Chair of the Board of Directors | Leuven, Belgium, June 12, 2025 – AstriVax Therapeutics NV, a clinical stage immunotherapy company developing novel treatments for chronic infections based on its proprietary Launch-iT technology, announced today the appointment of Dieter We... |
| 10.06.2025 | AstriVax Therapeutics Initiates Clinical Development of AVX70371, a Hepatitis B immunotherapy using LaunchiT technology | Leuven, Belgium, June 5, 2025 – AstriVax Therapeutics NV, a clinical stage immunotherapy
company developing novel treatments for chronic infections based on its proprietary Launch-iT
technology, announced today the start of clinical develop... |
| 21.05.2025 | Tubulis Achieves Key Milestone in BMS Strategic License Agreement as First Collaboration Tubutecan ADC Enters the Clinic | MUNICH, GERMANY, May 20, 2025 – Tubulis today announced that the first program from its strategic license agreement with Bristol Myers Squibb has entered clinical development, triggering a significant milestone in the ongoing collaboration ... |
| 29.04.2025 | Novadip releases five-year follow-up results for NVD003, regenerative treatment for severe bone non-union of lower limb | No refractures were reported during long-term follow-up at five years
At 24-months post-implantation, 89% of patients achieved bone union
Novadip plans market launch of NVD003 in 2027
Mont Saint-Guibert, Belgium, April 29, 2025 – Novadip Bi... |
| 24.04.2025 | Novadip reports key nonclinical and interim clinical data for NVDX3, its off-the-shelf allogeneic product, in spine fusion | Novadip reports key nonclinical and interim clinical data for NVDX3, its off-the-shelf allogeneic product, in spine fusion
NVDX3 elicited bone formation as early as 12 weeks and functional fusion by 26 weeks in ovine posterolateral fusion (... |
| 04.03.2025 | Minoryx gains FDA approval to initiate a Phase 3 clinical trial in patients with cerebral Adrenoleukodystrophy | Minoryx announces dosing of the first patient with leriglitazone in the phase 2a study in Rett syndrome (TREE study)
Barcelona, Spain – 4 March 2025 – Minoryx Therapeutics, a late-stage biotech company focused on the development of therapie... |
| 19.02.2025 | ONA Therapeutics Announces the Appointment of Dr Pamela Klein to its Board of Directors
Ona Therapeutics Strengthens Leadership Team to Accelerate First-in-Class ADCs into Clinical Development Across ... | • Dr. Aleix Prat, an internationally recognized leader in drug and biomarker development appointed Chair of the Advisory Board
• Dr. Jutta Amersdorffer appointed as Chief Medical Officer and Stéphane Durant des Aulnois appointed as Chief Fi... |
| 17.10.2024 | Novadip reports promising interim results from its first-in-human proof-of-concept trial with NVDX3, a new game changer in the bone field | At six months post-grafting surgery with NVDX3, x-rays demonstrate that 90% of patients have reached or are steadily progressing towards complete bone healing
Derived from Novadip’s 3M3 stem cell platform, NVDX3, a unique “Off the Shelf” al... |
| 29.07.2024 | Confo Therapeutics Announces EUR 60M Series B Financing to Advance Pipeline of Novel GPCR-Modulating Therapies into Clinical Development | • Proceeds to support Phase 1 clinical trials for two proprietary programs, and to advance two additional programs to IND approval
• Company to expand R&D efforts to discover additional development candidates for rare endocrine diseases... |
| 21.06.2024 | Tubulis Doses First Patient in Phase I/IIa Trial Investigating ADC Candidate TUB-040 in Ovarian Cancer and Lung Adenocarcinoma | The multicenter, first-in-human, dose escalation and optimization Phase I/IIa study aims to investigate the safety, tolerability, pharmacokinetics, and efficacy of TUB-040 as a monotherapy. The trial will be conducted in the US as well as t... |
| 09.04.2024 | Novo Nordisk to acquire Cardior Pharmaceuticals and strengthen pipeline in cardiovascular disease | Bagsværd, Denmark, and Hannover, Germany, 25 March, 2024 – Novo Nordisk and Cardior Pharmaceuticals today announced that Novo Nordisk has agreed to acquire Cardior for up to 1.025 billion Euros, including an upfront payment and additional p... |
| 14.03.2024 | Fund+ Portfolio Company Tubulis Closes Upsized EUR 128 Million Series B2 to Accelerate Clinical Development of Solid Tumor-Focused ADC Pipeline |
MUNICH, GERMANY, March 14, 2024 – Tubulis, a Fund+ portfolio company, today announced the successful completion of an upsized and oversubscribed EUR 128 million (USD 138.8 million) Series B2 financing. The round was co-led by EQT Life Scie... |
| 30.08.2023 | Confo Therapeutics Appoints Dieter Weinand, Former CEO of Bayer Pharmaceuticals, as Independent Chairman | Ghent, Belgium – August 29, 2023 – Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today announced the appointment of Dieter Weinand as Independent Chairman of its Board of Directors... |
| 15.06.2023 | Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera | • Collaboration to make use of Confo’s unique suite of ConfoBody®-enabled antibody discovery technologies on two GPCR targets
• Confo to receive upfront and milestone payments
• Tiered royalties payable to Confo on net sales from resulting ... |
| 05.06.2023 | ONA Therapeutics Announces the Appointment of Dr Pamela Klein to its Board of Directors | • Leading medical oncologist and seasoned biotechnology executive with significant experience in drug development |
| 05.06.2023 | Coave Therapeutics announces Positive 12-months Data from Ongoing Phase I/II Clinical Trial of CTx-PDE6b in Patients with Retinitis Pigmentosa Caused by Bi-allelic Mutations in PDE6b | – CTx-PDE6b demonstrated clinically meaningful benefit in visual functions at the highest dose and exhibits a good safety profile
– Positive results from the study to date support preparations for a registrational trial for CTx-PDE6b in PDE... |
| 05.06.2023 | Minoryx gains FDA approval to initiate a Phase 3 clinical trial in patients with cerebral Adrenoleukodystrophy | US trial with leriglitazone to commence in mid-2023 providing an FDA-approved route to US market whilst EMA evaluates European Marketing Authorization Application (MAA) |
| 15.05.2023 | Indigo Appoints Dr. Arun Venkatasubramanian as Chief Technology Officer | Arun is an award-winning engineer who brings over 15 years’ experience in leading the design and development of transformational technology within the medical, consumer, and military sectors |
| 25.04.2023 | Minoryx presents positive interim results from NEXUS registration study for leriglitazone targeting pediatric ALD patients with cerebral adrenoleukodystrophy (cALD) | Initial evidence of disease stabilization was demonstrated for all patients using radiological, clinical and plasma biomarker assessments at 6 months (24 weeks) of treatment |
| 20.04.2023 | Tubulis Announces Strategic License Agreement with Bristol Myers Squibb to Develop Next Generation ADCs for the Treatment of Cancer Patients | MUNICH, GERMANY, April 20, 2023 – Tubulis and Bristol Myers Squibb (NYSE: BMY) today announced
that they have entered into a strategic license agreement to develop differentiated antibody-drug
conjugates (ADCs). |
| 30.03.2023 | Confo Therapeutics Enters into Collaboration Agreement with Daiichi Sankyo to Discover Novel Medicines for CNS Diseases | Ghent, Belgium – March 30, 2023 – Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today announced that it has entered a collaboration agreement with Daiichi Sankyo (TSE: 4568) for th... |
| 13.03.2023 | ExeVir Bio and VIB Announce Data on a New Therapy for Prevention and Treatment for COVID-19. | Ghent, Belgium, 13 March 2023: ExeVir Bio, a biotech company developing robust single domain antibody therapies for broad protection against infectious diseases, and its scientific founders at Belgium’s VIB, Flanders’ leading life sciences ... |
| 02.03.2023 | Confo Therapeutics Announces Global Licensing Agreement with Lilly for Peripheral Pain Candidate, CFTX-1554 | Ghent, Belgium – March 2, 2023 – Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today announced a worldwide licensing agreement with Eli Lilly and Company for Confo’s clinical stage... |
| 30.01.2023 | Cellaion SA announces a total fundraising of EUR 23 million in 2022 for its phase IIB study in Acute on Chronic Liver Failure with Truffle Capital as lead investor in the final Closing followed by New... | Mont-Saint-Guibert, Belgium, 2023/01/13. Cellaïon is a biotechnology company based in Mont-St-Guibert, active in the field of cell therapy, an area of excellence in the life sciences industry in Wallonia. Its flagship product HepaStem®, in ... |
| 19.01.2023 | TargED Biopharmaceuticals announces the appointment of Erik van den Berg as Chair of its Supervisory Board | Utrecht, the Netherlands, January 19, 2023. TargED Biopharmaceuticals, a biotech spin-off of the University Medical Center Utrecht, announced today the appointment of Erik van den Berg as Chair and independent Board Member of its Supervisor... |
| 09.01.2023 | Belgium: ExeVir lands European venture debt financing to develop novel nanobody COVID-19 therapy | Gent, 9 January 2022 – The European Investment Bank (EIB) and ExeVir BIO BV (ExeVir) have signed a €25 million venture debt financing agreement to advance the development of ExeVir’s novel COVID-19 therapeutic. The financing is part of the ... |
| 27.12.2022 | Novadip Biosciences SA Appoints Judy Ashworth, MD, as Chief Medical Officer | Mont Saint-Guibert, Belgium – December 27, 2022 – Novadip Biosciences SA (“Novadip” or “the Company”), a clinical stage company developing treatments to regenerate impaired tissue in patients with significant unmet medical needs, today anno... |
| 09.12.2022 | Novadip Biosciences SA Announces Positive Results from Phase 1/2 Clinical Trial in Patients with Severe Bone Non-Union of the Lower Limb Following Trauma | Study results demonstrate NVD-003 has a favorable safety profile and convincing efficacy including rapid, durable bone healing in patients following failure of conventional treatment |
| 10.11.2022 | Minoryx and Neuraxpharm announce a strategic alliance to provide a new therapy for rare CNS disease patients in Europe9 | The companies enter into a license agreement for the European rights to leriglitazone, currently under EMA review for the orphan indication X-linked Adrenoleukodystrophy (X-ALD) |
| 04.11.2022 | Novadip Biosciences Raises Additional EUR 40 Million Bringing Total Company Funding to EUR 88 Million | Funding will support development of next generation orthopedic products that provide accelerated healing through single treatment cures |
| 20.10.2022 | ExeVir Bio Forges Ahead with Unique Next Generation COVID-19 Therapy and Appoints Dr. Jeanne Bolger as Chair of the Board of Directors | Targeting final lead therapy selection, neutralizing all known previous and current SARS-CoV2 variants of concern by end 2022 |
| 20.10.2022 | Coave Therapeutics Strengthens Board of Directors | Paris, France, October 20th, 2022 – Coave Therapeutics (‘Coave’), a biotech company leading the transition of genetic medicine from (ultra) rare to prevalent conditions in neurodegenerative diseases, today announces Frederic Chereau as Chai... |
| 30.09.2022 | Indigo Diabetes Announces First Participant Enrolled in the SHINE Clinical Trial | BELGIUM – Ghent, September 29, 2022 – Indigo Diabetes N.V. (‘Indigo’ or the ‘Company’), a pioneering developer of medical solutions using nanophotonics, today announces the enrollment of the first participant in Belgium in the SHINE clinica... |
| 26.09.2022 | Dr Jeanne Bolger to chair Board of Directors of Belgium-based vaccine technology company AstriVax | |
| 26.09.2022 | AstriVax, an innovative vaccine platform company, establishes scientific advisory board with world renowned leaders in vaccine development | • Emmanuel Hanon, PhD, will chair the company’s scientific advisory board.
• Professor Peter Piot {MD, PhD) and Professor Patrick Soentjens {MD, PhD) have been appointed as advisors.
• Together, they bring complementary expertise in infecti... |
| 20.09.2022 | Minoryx‘s Marketing Authorization Application for its lead candidate leriglitazone validated by EMA for orphan indication X-linked Adrenoleukodystrophy (X-ALD | Minoryx‘s Marketing Authorization Application for its lead candidate leriglitazone validated by EMA for orphan indication X-linked Adrenoleukodystrophy (X-ALD) |
| 20.09.2022 | Coave Therapeutics to Collaborate with World-Renowned Institute of Neurodegenerative Diseases of Bordeaux to Develop Gene Therapy Programs Targeting Protein Degradation in Neurodegenerative Disorders | Coave Therapeutics to Collaborate with World-Renowned Institute of Neurodegenerative Diseases of Bordeaux to Develop Gene Therapy Programs Targeting Protein Degradation in Neurodegenerative Disorders |
| 25.08.2022 | KU Leuven spin-off AstriVax raises € 30 million to build vaccine platform | KU Leuven spin-off AstriVax raises € 30 million to build vaccine platform |
| 17.08.2022 | Immunic Receives Notice of Allowance for Composition-of-Matter Patent in the United States for IMU-856, a Small Molecule Modulator Targeting Restoration of Intestinal Barrier Function and Regeneration... | Immunic Receives Notice of Allowance for Composition-of-Matter Patent in the United States for IMU-856, a Small Molecule Modulator Targeting Restoration of Intestinal Barrier Function and Regeneration of Bowel Epithelium |
| 27.07.2022 | Cardior Announces First Patient Dosed in Phase 2 Study Evaluating Efficacy and Safety of Non-coding RNABased Lead Candidate CDR132L in Heart Failure Patients PostMyocardial Infarction | Cardior Announces First Patient Dosed in Phase 2 Study Evaluating Efficacy and Safety of Non-coding RNABased Lead Candidate CDR132L in Heart Failure Patients PostMyocardial Infarction |
| 07.07.2022 | Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Maria Törnsén | Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Maria Törnsén |
| 31.05.2022 | Minoryx raises €51 million to support Marketing Authorization Application and launch preparations for X-linked Adrenoleukodystrophy (X-ALD) therapy
Minoryx raises €51 million to support Marketing Aut... | Funds will support the marketing authorization review process for male patients with AMN and launch preparations in Europe, as well as activities required for US approval pathway |
| 05.05.2022 | Immunic Announces Start of Patient Cohorts in Its Phase 1 Clinical Trial of IMU-856 in Celiac Disease | Immunic Announces Start of Patient Cohorts in Its Phase 1 Clinical Trial of IMU-856 in Celiac Disease |
| 03.05.2022 | Tubulis Closes €60 Million Series B Financing to Accelerate its ADC Pipeline and Expand its Breadth of Platform Technologies | Tubulis Closes €60 Million Series B Financing to Accelerate its ADC Pipeline and Expand its Breadth of Platform Technologies |
| 29.03.2022 | Cellaïon announces update to its Board of Directors: Dr. Fouzia LAGHRISSI-THODE joins the biotech as Member of the Board | Cellaïon announces update to its Board of Directors: Dr. Fouzia LAGHRISSI-THODE joins the biotech as Member of the Board |
| 10.03.2022 | Confo Therapeutics Doses First Subjects in Phase 1 Clinical Trial of CFTX-1554 for the Treatment of Neuropathic Pain | Confo Therapeutics Doses First Subjects in Phase 1 Clinical Trial of CFTX-1554 for the Treatment of Neuropathic Pain |
| 24.02.2022 | Immunic, Inc. Reports Year End 2021 Financial Results and Highlights Recent Activity | – Initiated Enrollment in Phase 3 ENSURE Program of Vidofludimus Calcium for the Treatment of Relapsing Multiple Sclerosis; Final Cohort 2 Data from the Phase 2 EMPhASIS Trial Confirms Phase 3 Dose Selection – |
| 22.02.2022 | TargED Biopharmaceuticals raises EUR 39 Million in Series A financing to bring groundbreaking thrombolytic treatment to patients | TargED Biopharmaceuticals raises EUR 39 Million in Series A financing to bring groundbreaking thrombolytic treatment to patients |
| 03.02.2022 | eTheRNA immunotherapies and Ghent University Announce mRNA Delivery Collaboration and License Agreement | Partnership Press Release |
| 13.01.2022 | Epics Therapeutics Initiates First-in-Human Studies with EP282, an oral Investigational Drug for the treatment of gastrointestinal inflammatory disorders and cancer. | - |
| 16.12.2021 | Confo Therapeutics Expands Patent Estate for ConfoBody®-based GPCR Screening Platform | Confo Therapeutics Expands Patent Estate for ConfoBody®-based GPCR Screening Platform |
| 14.12.2021 | Immunic, Inc. Publishes Positive Results from the Single and Multiple Ascending Dose Parts of its Phase 1 Clinical Trial of IMU-935, a Potentially Best-in-Class Oral IL-17 Inhibitor | – Unblinded Data Established a Favorable Safety and Tolerability Profile for IMU-935 in Single Dose and 14-Day Multiple Dose Assessments in Healthy Human Subjects – |
| 10.12.2021 | Immunic, Inc. Announces Enrollment of the First Patient in its Phase 1 Trial of IMU-935 in Metastatic Castration-Resistant Prostate Cancer | NEW YORK, Dec. 9, 2021 /PRNewswire/ — Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, to... |
| 02.12.2021 | ONA Therapeutics Appoints Dr Michel Detheux as Independent Chair to Board of Directors | ONA Therapeutics Appoints Dr Michel Detheux as Independent Chair to Board of Directors |
| 30.11.2021 | Confo Therapeutics Enters Collaborative Agreement with Regeneron | Confo Therapeutics Enters Collaborative Agreement with Regeneron |
| 22.11.2021 | Immunic, Inc. Announces Enrollment of First Patient in its Phase 3 ENSURE Program of vidofludimus calcium (IMU-838) in Relapsing Multiple Sclerosis | NEW YORK, Nov. 18, 2021 /PRNewswire/ — Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, t... |
| 04.11.2021 | Immunic, Inc. Reports Third Quarter 2021 Financial Results and Highlights Recent Activity | – Fully Enrolled Phase 2 CALDOSE-1 Trial of IMU-838 in Moderate-to-Severe Ulcerative Colitis – |
| 03.11.2021 | Additional data from Minoryx’s Phase 2/3 ADVANCE clinical trial presented at American Neurological Association (ANA) 2021
Presentation highlights reduction in cerebral lesion progression and the risk... | Mataró, Barcelona, Spain, November 3, 2021 – Minoryx Therapeutics, a Phase 3 clinical stage biotech company focused on the development of differentiating treatment options in orphan central nervous system (CNS) disorders, today announces th... |
| 28.10.2021 | Novadip Biosciences announces EUR 19 million Series B financing backed by international investors | Novadip Biosciences announces EUR 19 million Series B financing backed by international investors |
| 28.10.2021 | Immunic, Inc. Announces Completion of Enrollment of its Phase 2 CALDOSE-1 Trial of IMU-838 in Moderate-to-Severe Ulcerative Colitis | |
| 22.10.2021 | Egle Therapeutics raises 40 million € Series A to develop First-In-Class T-regulatory cells therapies based on Treg-starvers
About Egle Therapeutics
About LSP
About Bpifrance – InnoBio 2
About Tak... | Egle Therapeutics SAS (Egle), an emerging biotechnology company focused on developing First-In- Class immunotherapies targeting immune suppressor regulatory T-cells (Tregs) for oncology and autoimmune diseases, today announces that it has c... |
| 21.10.2021 | ONA Therapeutics Strengthens Scientific Leadership Team | ONA Therapeutics Strengthens Scientific Leadership Team |
| 19.10.2021 | Fund+ on LN24 | Very proud of FundPlus on LN24 in #successstories, #lifesciences #biotechs #investmentopportunities #clinicaldevelopment #financing (Fund+ as of 21min30sec in the #video) #LN24 #pierrehermant |
| 15.10.2021 | Immunic, Inc. Appoints Patrick Walsh as Chief Business Officer | NEW YORK, Oct. 14, 2021 /PRNewswire/ — Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, a... |
| 12.10.2021 | Coave Therapeutics appoints Olivier Danos and Frederic Chereau as non-executive directors to its Board | Coave Therapeutics appoints Olivier Danos and Frederic Chereau as non-executive directors to its Board
– Dr. Olivier Danos PhD, is currently Chief Scientific Officer of RegenxBio
– Frederic Chereau MBA, is currently President and CEO of Log... |
| 01.10.2021 | Immunic, Inc. Enrolls First Patient in Its Phase 2 CALLIPER Trial of IMU-838 in Progressive Multiple Sclerosis | NEW YORK, Sept. 30, 2021 /PRNewswire/ — Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, ... |
| 22.09.2021 | Immunic and the University Medical Center Goettingen Sign License Agreement Covering the Combination of DHODH Inhibitors and Nucleoside Analogues to Treat Viral Infections, Including COVID-19 | Immunic and the University Medical Center Goettingen Sign License Agreement Covering the Combination of DHODH Inhibitors and Nucleoside Analogues to Treat Viral Infections, Including COVID-19 |
| 16.09.2021 | Coave Therapeutics and Théa Open Innovation sign exclusive licensing, co-development and commercialization agreement for Europe for CTx-PDE6b, a novel gene therapy candidate in retinitis pigmentosa | Coave Therapeutics and Théa Open Innovation sign exclusive licensing, co-development and commercialization agreement for Europe for CTx-PDE6b, a novel gene therapy candidate in retinitis pigmentosa |
| 01.09.2021 | ExeVir Announces First Patient Enrolled in Phase 1b/2 Clinical Study evaluating XVR011 as antiviral treatment of patients hospitalised for COVID-19 | ExeVir Announces First Patient Enrolled in Phase 1b/2 Clinical Study evaluating XVR011 as antiviral treatment of patients hospitalised for COVID-19 |
| 25.08.2021 | Cardior Raises €64 M Series B to Advance Clinical Pipeline of RNA Therapeutics to Treat Cardiac Disease | Cardior Raises €64 M Series B to Advance Clinical Pipeline of RNA Therapeutics to Treat Cardiac Disease |
| 18.08.2021 | ExeVir announces first subjects dosed in Phase I clinical study of potent COVID-19 neutralizing antibody | ExeVir announces first subjects dosed |
| 22.07.2021 | Coave Therapeutics Closes €33 million ($39 million) Series B Financing to Develop its Gene Therapy Pipeline and Next-Generation Vectors based on its AAV-Ligand Conjugate Platform | Coave Therapeutics Closes €33 million ($39 million) Series B Financing to Develop its Gene Therapy Pipeline and Next-Generation Vectors based on its AAV-Ligand Conjugate Platform |
| 20.07.2021 | Immunic, Inc. Announces Closing of $45.0 Million Public Offering | Immunic, Inc. Announces Closing of $45.0 Million Public Offering |
| 15.07.2021 | eTheRNA immunotherapies and Ghent University Announce mRNA Delivery Collaboration and License Agreement | eTheRNA immunotherapies and Ghent University Announce mRNA Delivery Collaboration and License Agreement |
| 15.07.2021 | ExeVir and Mithra announce manufacturing collaboration for innovative Covid-19 treatments | ExeVir and Mithra announce manufacturing collaboration for innovative Covid-19 treatments |
| 13.07.2021 | ExeVir’s COVID-19 antibody candidate neutralizes coronavirus Variants of Concern | ExeVir’s COVID-19 antibody candidate neutralizes coronavirus Variants of Concern |
| 01.07.2021 | Immunic, Inc. Announces FDA Clearance to Begin IMU-838 Phase 3 ENSURE Studies in Relapsing-Remitting Multiple Sclerosis and Phase 2 CALLIPER Study in Progressive Multiple Sclerosis | Immunic, Inc. Announces FDA Clearance to Begin IMU-838 Phase 3 ENSURE Studies in Relapsing-Remitting Multiple Sclerosis and Phase 2 CALLIPER Study in Progressive Multiple Sclerosis |
| 29.06.2021 | eTheRNA immunotherapies and Quantoom Biosciences Announce a Strategic Collaboration for the Development of a Novel RNA Production System | eTheRNA immunotherapies and Quantoom Biosciences Announce a Strategic Collaboration for the Development of a Novel RNA Production System |
